ReviewFrontiers in immunology2014
Regulatory B cells: an exciting target for future therapeutics in transplantation.
Review in Frontiers in immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 50 citations in OpenAlex.
- Comprehensive Phenotyping and Cytokine Production of Circulating B Cells Associate Resting Memory B Cells With Early Antibody-mediated Rejection in Kidney Transplant Recipients.Transplantation direct · 2025Article
- Relationship of transitional regulatory B and regulatory T cells and immunosuppressive drug doses in stable renal transplant recipients.Immunity, inflammation and disease · 2021Article
- Metabolic Program of Regulatory B Lymphocytes and Influence in the Control of Malignant and Autoimmune Situations.Frontiers in immunology · 2021Review
- Regulatory and IgEMethods in molecular biology (Clifton, N.J.) · 2021Article
- The proportion of CD19Annals of translational medicine · 2019Article
- Wuchereria bancrofti-infected individuals harbor distinct IL-10-producing regulatory B and T cell subsets which are affected by anti-filarial treatment.PLoS neglected tropical diseases · 2019Article
- The Number of Regulatory B Cells is Increased in Mice with Collagen-induced Arthritis.Open life sciences · 2019Article
- Correlation Between Stem and Progenitor Cells Number and Immune Response in Patients After Allogeneic Kidney Transplant.Annals of transplantation · 2018Article
- Regulatory B cells: the cutting edge of immune tolerance in kidney transplantation.Cell death & disease · 2018Review
- CD9Frontiers in immunology · 2018Observational
- Expanding Diversity and Common Goal of Regulatory T and B Cells. II: In Allergy, Malignancy, and Transplantation.Archivum immunologiae et therapiae experimentalis · 2017Review
- Regulatory and Memory B Lymphocytes in Children With Newly Diagnosed Immune Thrombocytopenia.Journal of hematology · 2017Article
- Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu.Blood cancer journal · 2017Article
- Human regulatory B cells in health and disease: therapeutic potential.The Journal of clinical investigation · 2017Review
- T regulatory cell mediated immunotherapy for solid organ transplantation: A clinical perspective.Molecular medicine (Cambridge, Mass.) · 2017Article
- A Paradigm Shift on the Question of B Cells in Transplantation? Recent Insights on Regulating the Alloresponse.Frontiers in immunology · 2017Review
- Tolerance in Kidney Transplantation: What Is on the B Side?Mediators of inflammation · 2016Review
- Article
- Increased circulating follicular helper T cells with decreased programmed death-1 in chronic renal allograft rejection.BMC nephrology · 2015Article
- The expanding family of regulatory B cells.International immunology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transplantation is the preferred treatment for most end-stage solid organ diseases. Despite potent immunosuppressive agents, chronic rejection remains a real problem in transplantation. For many years, the predominant immunological focus of research into transplant rejection has been T cells. The pillar of immunotherapy in clinical practice is T cell-directed, which efficiently prevents acute T cell-mediated allograft rejection. However, the root of late allograft failure is chronic rejection and the humoral arm of the immune response now emerges as an important factor in transplantation. Thus, the potential effects of Abs and B cell infiltrate on transplants have cast B cells as major actors in late graft rejection. Consequently, a number of recent drugs target either B cells or plasma cells. However, immunotherapies, such as the anti-CD20 B cell-depleting antibody, can generate deleterious effects on the transplant, likely due to the deletion of beneficial population. The positive contribution of regulatory B (Breg) cells or B10 cells has been reported in the case of transplantation, mainly in mice models and highlights the primordial role that some populations of B cells can play in graft tolerance. Yet, this regulatory aspect remains poorly characterized in clinical transplantation. Thus, total B cell depletion treatments should be avoided and novel approaches should be considered that manipulate the different B cell subsets. This article provides an overview of the current knowledge on the link between Breg cells and grafts, and reports a number of data advising Breg cells as a new target for future therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.